MedElevator
Войти в исследования Journal of Alzheimer's disease reports · 2026
Association between the coronavirus disease pandemic and antipsychotic drug prescriptions among patients with dementia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hurh Kyungduk, Kim Hyunkyu, Park Eun-Cheol
Аннотация
BACKGROUND: Antipsychotics are frequently prescribed off-label to manage behavioral and psychological symptoms of dementia but pose safety risks in older adults, including a 1.5-2.0-fold increased risk of mortality. The coronavirus disease (COVID-19) pandemic disrupted dementia care, increasing reliance on pharmacologic treatments.
OBJECTIVE: This study aimed to evaluate whether the COVID-19 pandemic was associated with changes in the prevalence of antipsychotic prescribing among patients with dementia.
METHODS: Using the Korean National Health Insurance Database, this study analyzed a random 50% sample of eligible individuals aged ≥60 years diagnosed with dementia between 2016 and 2021 (n = 876,158; 9.8 million person-observations). Outcomes included the likelihood, duration, and number of antipsychotic prescriptions issued, characterizing pharmacologic management of dementia. Interrupted time series analysis assessed associations between the pandemic and relative changes in these outcomes, adjusting for demographic factors, comorbid burden, and seasonality.
RESULTS: After the pandemic onset, there were relative slope increases per quarter of 1.5%, 3.2%, and 0.4% in the likelihood, duration, and number of prescriptions, respectively (all p < 0.001; pre-pandemic levels: 0.172 patients prescribed, 12.97 days, and 18.10 prescriptions per person-quarter). Antipsychotic prescriptions decreased by 1.6% (p < 0.001) during the first quarter after the outbreak but subsequently showed a progressive increase, reflecting prolonged care disruption after initial access barriers.
CONCLUSIONS: The COVID-19 pandemic was associated with increased antipsychotic prescribing among patients with dementia. To mitigate similar effects in future public health crises, governments and healthcare providers should strengthen mental health support, non-pharmacological interventions, telehealth continuity, and tailored prescribing guidelines.
OBJECTIVE: This study aimed to evaluate whether the COVID-19 pandemic was associated with changes in the prevalence of antipsychotic prescribing among patients with dementia.
METHODS: Using the Korean National Health Insurance Database, this study analyzed a random 50% sample of eligible individuals aged ≥60 years diagnosed with dementia between 2016 and 2021 (n = 876,158; 9.8 million person-observations). Outcomes included the likelihood, duration, and number of antipsychotic prescriptions issued, characterizing pharmacologic management of dementia. Interrupted time series analysis assessed associations between the pandemic and relative changes in these outcomes, adjusting for demographic factors, comorbid burden, and seasonality.
RESULTS: After the pandemic onset, there were relative slope increases per quarter of 1.5%, 3.2%, and 0.4% in the likelihood, duration, and number of prescriptions, respectively (all p < 0.001; pre-pandemic levels: 0.172 patients prescribed, 12.97 days, and 18.10 prescriptions per person-quarter). Antipsychotic prescriptions decreased by 1.6% (p < 0.001) during the first quarter after the outbreak but subsequently showed a progressive increase, reflecting prolonged care disruption after initial access barriers.
CONCLUSIONS: The COVID-19 pandemic was associated with increased antipsychotic prescribing among patients with dementia. To mitigate similar effects in future public health crises, governments and healthcare providers should strengthen mental health support, non-pharmacological interventions, telehealth continuity, and tailored prescribing guidelines.